AbbVie Inc (ABBV)vsWW International, Inc. Common Stock (WW)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
WW
WW International, Inc. Common Stock
$16.25
-5.88%
HEALTHCARE · Cap: $185.48M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 8974% more annual revenue ($62.82B vs $692.33M). WW leads profitability with a 155.5% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.59. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
WW
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for WW.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 405 in profit
Keeps 156 of every $100 in revenue as profit
Earnings expanding 5268.0% YoY
Safe zone — low bankruptcy risk
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
Elevated debt levels
Expensive relative to growth rate
Revenue declined 9.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : WW
The strongest argument for WW centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 155.5% and operating margin at -16.9%.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : WW
The primary concerns for WW are Market Cap, Debt/Equity, PEG Ratio. Debt-to-equity of 1.76 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while WW is a declining play — different risk/reward profiles.
WW carries more volatility with a beta of 1.06 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 58/100) and 12.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
WW International, Inc. Common Stock
HEALTHCARE · MEDICAL CARE FACILITIES · USA
WW International, Inc. offers worldwide weight management products and services. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?